Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...4445464748495051525354...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment open, Checkpoint inhibition:  Indi-Blade: Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (clinicaltrials.gov) -  Apr 18, 2023   
    P2,  N=50, Recruiting, 
    N=12 --> 56 | Trial completion date: Mar 2024 --> Mar 2027 | Trial primary completion date: Mar 2024 --> Mar 2027 Active, not recruiting --> Recruiting
  • ||||||||||  Review, Journal, Metastases:  Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. (Pubmed Central) -  Apr 17, 2023   
    P2
    A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. Many other combination treatments, such as pembrolizumab plus lenvatinib plus belzutifan (NCT04976634), are being investigated, possibly leading to more options in the first-line setting in the future.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, IO biomarker, Metastases:  Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. (Pubmed Central) -  Apr 17, 2023   
    P1
    Altogether, activity of combined decitabine and ipilimumab is impacted by cellular expression states within the microenvironmental niche of leukemia cells. The inadequate elimination of leukemic progenitors mandates urgent development of novel approaches for targeting these cell populations to generate long-lasting responses.
  • ||||||||||  SQZ-PBMC-HPV / STEMCELL Technologies
    Trial completion, Enrollment change, Trial completion date, Monotherapy, Checkpoint inhibition:  SQZ-PBMC-HPV-101: Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Apr 14, 2023   
    P1,  N=30, Completed, 
    These findings shed new light on the impact of ICIs on state Medicaid programs and may provide insight into potential cost drivers that need to be addressed through policy. Active, not recruiting --> Completed | N=200 --> 30 | Trial completion date: Jun 2023 --> Feb 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Clinical, Journal, Adverse events, Checkpoint inhibition, Metastases:  Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. (Pubmed Central) -  Apr 13, 2023   
    Our study underlines that checkpoint inhibitors used for melanoma increase CVAEs, especially dyslipidemia, which could pave the way to chronic inflammatory processes, atherosclerosis, and, finally, ischemic cardiopathy. These cardiovascular adverse events could be acute or delayed, justifying the monitoring of lipidic biology and a baseline cardiology consultation.
  • ||||||||||  nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
    Trial primary completion date, Checkpoint inhibition:  PERIO-02: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors (clinicaltrials.gov) -  Apr 13, 2023   
    P1b/2,  N=89, Recruiting, 
    The Shiny method allowed us to perform all head-to-head indirect comparisons between these agents in a context in which "real" comparative trials have not been performed. Trial primary completion date: Jan 2023 --> Aug 2023
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Downstaging hepatocellular carcinoma with checkpoint inhibitor therapy safely improves access to curative liver transplantation: a case series (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1115;    
    The 3 cases who ultimately received a liver transplant demonstrated no evidence of rejection or recurrence up to 2 years post-transplant. Future studies are needed to further assess the outcomes of a larger sample size as well as evaluate areas of interest, such as optimal timing of CPIT discontinuation prior to transplant and to assess whether novel tumor biomarkers may provide insight into which patients will respond to this intervention.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
    Bio-active lipids protect against immune-related adverse events due to immune checkpoint blockade therapy (P514) (Exhibit Hall; Poster Board No. P514) -  Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_1192;    
    Our recent study of plasma from patients undergoing ipilimumab (anti-CTLA4) or pembrolizumab (anti-PD1) therapy for melanoma, lung cancer or other solid tumors was assessed using high-resolution liquid chromatography-tandem mass spectrometry. These results uncover a previously unidentified regulatory mechanism whereby the identified lipids in circulation specifically suppress deleterious inflammation during ICB therapy, while preserving anti-tumor immunity, suggesting that supplementation of bio-active lipids can be developed as a new therapeutic strategy to improve clinical outcomes in cancer immunotherapy.
  • ||||||||||  Journal:  Top advances of the year: Head and neck cancer. (Pubmed Central) -  Apr 11, 2023   
    However, in an important breakthrough for patients with nasopharyngeal cancer, the JUPITER-02 trial, conducted in China, Singapore, and Taiwan among patients with predominantly Epstein-Barr virus-related cancers, demonstrated a significant improvement in PFS (hazard ratio, 0.52) when toripalimab was added to gemcitabine/cisplatin chemotherapy. Immature survival data indicate overall survival will likely also be impacted.
  • ||||||||||  Clinical, Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials. (Pubmed Central) -  Apr 11, 2023   
    In patients with PD-L1+ve and -ve ccRCC, niv, atezolizumab, ipi, and pembrolizumab were safe and effective alone and when combined with cabozantinib, tivozanib, axitinib, levantinib, and pegilodecakin...Pembrolizumab was safe and effective in preventing recurrence in ccRCC patients with nephrectomy. Additional randomized, double-blind, multicenter clinical trials are needed to confirm these results.
  • ||||||||||  Ezharmia (valemetostat) / Daiichi Sankyo, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Metastases:  DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (clinicaltrials.gov) -  Apr 7, 2023   
    P1,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting | N=84 --> 2 | Trial completion date: Aug 2027 --> Aug 2023 | Trial primary completion date: Feb 2025 --> Aug 2022 Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Apr 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker:  Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. (Pubmed Central) -  Apr 4, 2023   
    The results of clinical findings that evaluated the combination of ipilimumab and nivolumab are then summarized to support future research in the field of combination therapy. Finally, the irAEs associated with combined ICI therapy, as well as the underlying biomarkers involved in their management, are discussed.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial primary completion date, Checkpoint inhibition, IO biomarker:  CPIT-002: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (clinicaltrials.gov) -  Apr 4, 2023   
    P1,  N=8, Active, not recruiting, 
    We report on the discovery of a novel epigenetic phenotype associated with resistance to immune checkpoint inhibitors that may pave the way to better personalizing patients' treatments. Trial primary completion date: Jan 2023 --> Jan 2024